Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

Fig. 2

High serum ADAM12 levels associate with unfavorable outcome. A Serum levels of ADAM12 were measured by ELISA in 235 patients from the CAIRO2 cohort, and patients in the two trial arms were dichotomized by ADAM12 levels (222 pg/mL). Survival analysis by Kaplan-Meier is shown. B Absolute serum levels of ADAM12 were stratified by KRAS and BRAF mutant or wildtype. Significance is tested by unpaired two tailed Student’s t-test. C Kaplan-Meier analysis in the KRAS and BRAF wildtype cohort, dichotomized by serum ADAM12. D Kaplan-Meier analysis in the KRAS and BRAF mutant cohort, dichotomized by serum ADAM12

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us